ES2188538T3 - Uso de 15-desoxipergualina para el tratamiento de enfermedades inflamatorias hiperreactivas y enfermedades autoinmunes. - Google Patents

Uso de 15-desoxipergualina para el tratamiento de enfermedades inflamatorias hiperreactivas y enfermedades autoinmunes.

Info

Publication number
ES2188538T3
ES2188538T3 ES00926953T ES00926953T ES2188538T3 ES 2188538 T3 ES2188538 T3 ES 2188538T3 ES 00926953 T ES00926953 T ES 00926953T ES 00926953 T ES00926953 T ES 00926953T ES 2188538 T3 ES2188538 T3 ES 2188538T3
Authority
ES
Spain
Prior art keywords
treatment
diseases
deoxipergualine
autoimmune diseases
inflammatory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00926953T
Other languages
English (en)
Inventor
Rainer Birck
Johannes Drexler
Osamu Hotta
Rainer Nowack
Der Woude Fokku Johannes Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Nippon Kayaku GmbH
Nippon Kayaku Co Ltd
Original Assignee
Euro Nippon Kayaku GmbH
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Nippon Kayaku GmbH, Nippon Kayaku Co Ltd filed Critical Euro Nippon Kayaku GmbH
Application granted granted Critical
Publication of ES2188538T3 publication Critical patent/ES2188538T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

El uso de desoxiespergualina (DSG) o un análogo de la misma para la preparación de un medicamento para el tratamiento y/o la profilaxis frente a enfermedades inflamatorias hiperreactivas y enfermedades autoinmunes, realizándose el tratamiento en dos o más ciclos de tratamiento (bloques) que están separados entre sí por un periodo de tiempo que es considerablemente más largo que el periodo de tiempo entre dos administraciones sucesivas dentro de un ciclo de tratamiento.
ES00926953T 1999-05-25 2000-04-14 Uso de 15-desoxipergualina para el tratamiento de enfermedades inflamatorias hiperreactivas y enfermedades autoinmunes. Expired - Lifetime ES2188538T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19923961A DE19923961A1 (de) 1999-05-25 1999-05-25 Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen

Publications (1)

Publication Number Publication Date
ES2188538T3 true ES2188538T3 (es) 2003-07-01

Family

ID=7909146

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00926953T Expired - Lifetime ES2188538T3 (es) 1999-05-25 2000-04-14 Uso de 15-desoxipergualina para el tratamiento de enfermedades inflamatorias hiperreactivas y enfermedades autoinmunes.

Country Status (20)

Country Link
US (2) US7153887B1 (es)
EP (1) EP1180026B1 (es)
JP (2) JP4422349B2 (es)
KR (1) KR100681626B1 (es)
CN (1) CN1199636C (es)
AR (1) AR024071A1 (es)
AT (1) ATE228833T1 (es)
AU (1) AU762018B2 (es)
BR (1) BR0008637A (es)
CA (1) CA2362582C (es)
CZ (1) CZ299440B6 (es)
DE (2) DE19923961A1 (es)
ES (1) ES2188538T3 (es)
HU (1) HU228843B1 (es)
MX (1) MXPA01008587A (es)
PL (1) PL352314A1 (es)
RU (1) RU2255732C2 (es)
TW (1) TWI283175B (es)
WO (1) WO2000071103A2 (es)
ZA (1) ZA200106596B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1689435A4 (en) * 2003-10-22 2007-10-03 Univ Rochester ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS
AR048210A1 (es) * 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
WO2007121233A1 (en) * 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
FR2698628B1 (fr) * 1992-12-02 1995-02-17 Fournier Ind & Sante Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
US5250442A (en) * 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
FR2716452B1 (fr) * 1994-02-24 1996-05-10 Fournier Ind & Sante Analogues de la 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
ES2124926T3 (es) * 1994-03-22 1999-02-16 Nippon Kayaku Kk Uso de desoxipergualina para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias e hiperreactivas.
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
FR2734263B1 (fr) * 1995-05-17 1997-06-20 Fournier Ind & Sante Analogues de la 15-deoxyspergualine, leur procede de preparation et leur utilisation en therapeutique
US5679651A (en) * 1995-06-05 1997-10-21 Richardson; Bruce C. Treatment for systemic lupus erythematosus
DE19711803A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung mit 15-Deoxyspergualin
DE19728436A1 (de) * 1997-07-03 1999-01-07 Niels Franke Niedrigdosierte 15-Desoxyspergualin-Präparate
TW536400B (en) * 1997-07-18 2003-06-11 Nippon Kayaku Kk Pharmaceutical composition for the treatment of immunodeficiency disease which cause by HIV infection

Also Published As

Publication number Publication date
US7153887B1 (en) 2006-12-26
US20060293391A1 (en) 2006-12-28
CN1351490A (zh) 2002-05-29
KR100681626B1 (ko) 2007-02-09
MXPA01008587A (es) 2003-06-24
US7776829B2 (en) 2010-08-17
CN1199636C (zh) 2005-05-04
EP1180026B1 (en) 2002-12-04
DE60000937D1 (de) 2003-01-16
KR20020010126A (ko) 2002-02-02
TWI283175B (en) 2007-07-01
HU228843B1 (en) 2013-06-28
RU2255732C2 (ru) 2005-07-10
CA2362582A1 (en) 2000-11-30
CZ20014158A3 (cs) 2002-06-12
DE19923961A1 (de) 2000-11-30
AU4550400A (en) 2000-12-12
DE60000937T2 (de) 2003-09-04
JP2003500351A (ja) 2003-01-07
EP1180026A2 (en) 2002-02-20
HUP0200354A2 (hu) 2002-05-29
PL352314A1 (en) 2003-08-11
WO2000071103A3 (en) 2001-06-21
BR0008637A (pt) 2002-01-08
JP4422349B2 (ja) 2010-02-24
AR024071A1 (es) 2002-09-04
AU762018B2 (en) 2003-06-19
WO2000071103A2 (en) 2000-11-30
ATE228833T1 (de) 2002-12-15
JP2009263397A (ja) 2009-11-12
CA2362582C (en) 2008-10-07
HUP0200354A3 (en) 2003-03-28
ZA200106596B (en) 2002-08-12
CZ299440B6 (cs) 2008-07-30

Similar Documents

Publication Publication Date Title
ES2186667T3 (es) Analogos de nucleosidos de 1,3-oxatiolano.
DE59410116D1 (de) Kombinationsprodukt zur kontrazeption enthaltend progesteronantagonisten und gestagenen
ES2172533T3 (es) Uso de nonapeptidos y decapeptidos para la preparacion de un medicamento para combatir el sida.
TR199902994T2 (xx) K�r�k veya hastal�kl� kemi�in tadavisinde geni�leyebilir cisimler kullanan sistemler.
NL300258I2 (nl) Farmaceutische samenstelling voor toepassing in debehandeling van.
BG106030A (en) Pharmaceutical composition
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
DE69033970D1 (de) Huperzin a analoge verbindungen
ES2184341T3 (es) Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.
BR0207066A (pt) Derivados do 2h-1-benzopirano - processos para sua preparação e composições farmacêuticas a partir deles
ES2188538T3 (es) Uso de 15-desoxipergualina para el tratamiento de enfermedades inflamatorias hiperreactivas y enfermedades autoinmunes.
PT1017667E (pt) 2-amino-6-metil-7-acetil-tetralina e composicoes farmaceuticas para a prevencao e para o tratamento terapeutico de patologias inflamatorias e/ou de natureza autoimunitaria
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
UY27312A1 (es) Nuevos heterociclos 3
TR199801439T2 (xx) Herpes simpleks enfeksiyonlar�n�n kombine terapisinde n�kleosit analoglar�.
MX9301879A (es) Medicamento para el tratamiento de la inflamacion de las vias respiratorias
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine
ES2188140T3 (es) Utilizacion del factor de crecimiento de monocitos cd137 o un analogo funcional del mismo para producir un medicamento.
ES2150034T3 (es) Empleo de las 2-aminotetralinas substituidas en 6,7 para la preparacion de composiciones farmaceuticas de utilidad para el tratamiento del choque septico, y composiciones farmaceuticas antipireticas y antiinflamatorias.
ES2167942T3 (es) Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes.
NO952483D0 (no) Seskviterpener, deres fremstilling og anvendelse som inhibitorer innvirkende på gababenzodiazepinreseptorer
CO4790095A1 (es) Derivados de tienoxacinona inhibodores de la proteasa del herpes